In recent years, inflammation has become an increasingly hot topic in the medical community. This is because inflammation has been linked to a wide variety of health problems, ranging from heart disease and arthritis to Alzheimer’s and cancer. As a result, many pharmaceutical companies have begun researching ways to diagnose and treat inflammation.
Major names like Johnson & Johnson (NYSE: JNJ), AbbVie (NYSE: ABBV), and Pfizer (NYSE: PFE) are all looking into developing a treatment for the issue.
Another company, Precision Genomics, which is a division of Ludwig (OTC: LUDG), is also trying to develop an effective treatment for inflammation. However, rather than taking the traditional route of developing a new drug, Precision Genomics is utilizing its new mRNA technology to potentially diagnose and treat the root cause of inflammation.
Precision Genomics’ approach to treating inflammation is based on its new mRNA technology. This technology utilizes common genetic markers in our genomes to not only predict illnesses but also treat them before they even appear. In regards to inflammation specifically, Precision Genomics’ technology can be used to accurately diagnosis the root cause of chronic inflammation. Once the root cause has been identified, Precision Genomics’ mRNA technology can be used to develop a personalized treatment plan that targets the specific genes responsible for causing chronic inflammation.
Featured: $JNJ $ABBV $PFE $LUDG
